FDA Determines Regulatory Review Period for NUCALA Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for NUCALA, a human biological product, as required by law, following a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension.